Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Materialise and Tissue Regeneration Systems To Partner On 3-D Printed Tracheal Splints Clinical Trial

XTALKS NEWS

Infant Patient

The new clinical trial will use 3-D printed tracheal splints in order to treat infants diagnosed with tracheobronchomalacia (TBM) – a disease that can cause spontaneous collapse of the patient’s airway.

Share this!

December 9, 2015 | by Sarah Massey, M.Sc.

3-D printing software developer, Materialise, has announced it will be expanding its medical 3-D printing unit by partnering with startup, Tissue Regeneration Systems (TRS) to manufacture and test 3-D printed bioresorbable tracheal splints. The Belgium-based Materialise will also be using technology licensed from the University of Michigan, in order to push the tracheal splints into clinical trials.

TRS was the first company to receive US Food and Drug Administration (FDA) approval for their 3-D printed, bioresorbable skeletal reconstruction implant in 2013. The implant was coated with the company’s Cranial Bone Void Filler and used to repair holes made in the skull during neurosurgery.

In 2014, Johnson & Johnson formed a partnership with TRS in an effort to bulk up the company’s offerings in the 3-D printing space. The new clinical trial will use 3-D printed tracheal splints in order to treat infants diagnosed with tracheobronchomalacia (TBM) – a disease that can cause spontaneous collapse of the patient’s airway.



Approximately 1 in every 2,200 children are affected by TBM. In an effort to increase treatment offerings, the FDA has given the Expanded Access designation for devices designed to treat TBM.

“The collaboration between TRS and Materialise will provide production capacity for the tracheal splint, which will allow the splint to be available to a larger number of infants who are affected with TBM,” said Bryan Crutchfield, the USA managing director for Materialise. Using Materialise’s Mimics Innovation Suite, Glenn Green and Scott Hollister – both professors from the University of Michigan – designed and built tracheal splints based on an individual patient’s anatomy.

It’s expected that a clinical trial testing the splints will begin in 2016, featuring 30 patients at C.S. Mott Children's Hospital. “It was the possibility to realize 3D-printing enabled medical applications that, in part, motivated me to start Materialise 25 years ago,” said Fried Vancraen, founder and CEO of Materialise. “Today, we are proud to offer an entire range of software and services that can help universities, research centers, medical device companies, and hospitals develop solutions that result in a better and healthier world, such as the treatment developed for children diagnosed with TBM.”

Sources:

WATCH & PARTICIPATE IN THESE WEBINARS 


 

FDA Expectations for 503B Outsourcing Facilities

Food Defense Vulnerability Assessment: 3 Things You Need to Know to Prepare for the Food Safety Modernization Act (FSMA)


Keywords: Clinical Trial, 3-D Printing, FDA


| NEXT ARTICLE | MORE NEWS |

Share this with your colleagues!

READ THESE NEXT
Roche Collaborates With SQZ Biotech Startup On Immuno-Oncology Treatments

December 8, 2015 - Pharmaceutical giant Roche, has developed a partnership with Cambridge, Massachusetts-based SQZ Biotech to take advantage of the startup’s new take on cell engineering.


Evolution Of Gut Bacteria Affected By Host Immune System

December 7, 2015 - A new study conducted at the Instituto Gulbenkian de Ciência (IGC) in Portugal, suggests that the evolution of beneficial bacteria in the human gut may be influenced by the immune system.


Researchers Deactivate Cancer-Causing Proteins

December 4, 2015 - After 30 years of study by researchers around the world, a team of scientists at the University of Toronto in Canada, have developed an inhibitor drug for the cancer-causing protein, Ras.


LEAVE A COMMENT
 
Copyright © 2016-2017 Honeycomb Worldwide Inc.